Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Breast Cancer Reports
Erschienen in:

27.02.2024 | Review

Contemporary Management of Phyllodes Tumors

verfasst von: Tina Bharani, Laura S. Dominici

Erschienen in: Current Breast Cancer Reports | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purposeof Review

Phyllodes tumors (PT) are rare fibroepithelial lesions of the breast. It is critical to understand the behavior of benign, borderline, and malignant PT so as to recommend appropriate treatment. This review describes findings on diagnostic testing and pathology that differentiate these tumors, as well as recommended management.

Recent Findings

Better understanding of outcomes following PT resection has led to changes in local therapy recommendations, with wide margins (> 1 cm) strongly recommended for malignant PT only. Other PT may be resected with smaller (or no) margin without impact on local recurrence risk. Adjuvant radiation should be considered in malignant PT or when local recurrence would lead to significant morbidity.

Summary

Benign and borderline PT may not require wide margins at excision for optimal local control. Malignant PT should be resected with wide margins and consideration given to adjuvant radiation therapy.
Literatur
1.
Fiks A. Cystosarcoma phyllodes of the mammary gland–Muller’s tumor. For the 180th birthday of Johannes Muller. Virchows Arch A Pathol Anat Histol. 1981;392(1):1–6.PubMedCrossRef
2.
Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw. 2007;5(3):324–30.PubMedCrossRef
3.
Zhang Y, Kleer CG. Phyllodes tumor of the breast: histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med. 2016;140(7):665–71.PubMedCrossRef
4.
Mitus JW, Blecharz P, Jakubowicz J, Reinfuss M, Walasek T, Wysocki W. Phyllodes tumors of the breast. The treatment results for 340 patients from a single cancer centre. Breast. 2019;43:85–90.PubMedCrossRef
5.
Tan PH, Thike AA, Tan WJ, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol. 2012;65(1):69–76.PubMedCrossRef
6.
7.
Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006;107(9):2127–33.PubMedCrossRef
8.
Barrio AV, Clark BD, Goldberg JI, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007;14(10):2961–70.PubMedCrossRef
9.
Konstantakos AK, Graham DJ. Cystosarcoma phyllodes tumors in men. Am Surg. 2003;69(9):808–11.PubMedCrossRef
10.
Sain B, Gupta A, Ghose A, et al. Clinico-pathological factors determining recurrence of phyllodes tumors of the breast: the 25-year experience at a tertiary cancer centre. J Pers Med. 2023;13(5):866.
11.
Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20(34):4621–8.PubMedCrossRef
12.
13.
Tan J, Ong CK, Lim WK, et al. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 2015;47(11):1341–5.PubMedCrossRef
14.
Piscuoglio S, Geyer FC, Burke KA, et al. Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. NPJ Breast Cancer. 2016;2:16035.PubMedPubMedCentralCrossRef
15.
Mishima C, Kagara N, Tanei T, et al. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing. Breast Cancer Res Treat. 2015;152(2):305–12.PubMedCrossRef
16.
Piscuoglio S, Murray M, Fusco N, et al. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. Histopathology. 2015;67(5):719–29.PubMedPubMedCentralCrossRef
17.
Pareja F, Geyer FC, Kumar R, et al. Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. NPJ Breast Cancer. 2017;3:40.PubMedPubMedCentralCrossRef
18.
Ofri A, Stuart KE, Chan B, et al. Diagnosis and management of phyllodes tumours for the surgeon: an algorithm. Surgeon. 2022;20(6):e355–65.PubMedCrossRef
19.
Fernandez-Ferreira R, Arroyave-Ramirez A, Motola-Kuba D, Alvarado-Luna G, Mackinney-Novelo I, Segura-Rivera R. Giant benign mammary phyllodes tumor: report of a case and review of the literature. Case Rep Oncol. 2021;14(1):123–33.PubMedPubMedCentralCrossRef
20.
Jing P, Wei B, Yang X. Phyllodes tumor of the breast with nipple discharge: a case report. Medicine (Baltimore). 2018;97(52): e13767.PubMedCrossRef
21.
Ahmed MA, Habis S, Mahmoud A, Plurad DS, Saeed RAM, Elias D. Phyllodes tumor presenting as a fungating breast mass, nipple retraction, and bloody nipple discharge. Breast J. 2019;25(5):988.PubMedCrossRef
22.
Guerrero MA, Ballard BR, Grau AM. Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol. 2003;12(1):27–37.PubMedCrossRef
23.
Gullett NP, Rizzo M, Johnstone PA. National surgical patterns of care for primary surgery and axillary staging of phyllodes tumors. Breast J Jan-Feb. 2009;15(1):41–4.CrossRef
24.
Gan SY, Yahya MM, Wan Zain WZ, Nik Min NFA, Wan Abdul Rahman WF. The enigma of giant phyllodes tumour. Cureus. 2022;14(3):e22946.PubMedPubMedCentral
25.
26.
Tan H, Zhang S, Liu H, et al. Imaging findings in phyllodes tumors of the breast. Eur J Radiol. 2012;81(1):e62-69.PubMedCrossRef
27.
Foxcroft LM, Evans EB, Porter AJ. Difficulties in the pre-operative diagnosis of phyllodes tumours of the breast: a study of 84 cases. Breast. 2007;16(1):27–37.PubMedCrossRef
28.
Ward ST, Jewkes AJ, Jones BG, et al. The sensitivity of needle core biopsy in combination with other investigations for the diagnosis of phyllodes tumours of the breast. Int J Surg. 2012;10(9):527–31.PubMedCrossRef
29.
Yii N, Read T, Tan CC, Ng SL, Bennett I. Diagnosing phyllodes tumours of the breast: how successful are our current preoperative assessment modalities? ANZ J Surg. 2018;88(10):988–92.PubMedCrossRef
30.
Duman L, Gezer NS, Balci P, et al. Differentiation between phyllodes tumors and fibroadenomas based on mammographic sonographic and MRI features. Breast Care (Basel). 2016;11(2):123–7.PubMedCrossRef
31.
32.
Kalambo M, Adrada BE, Adeyefa MM, et al. Phyllodes tumor of the breast: ultrasound-pathology correlation. AJR Am J Roentgenol. 2018;210(4):W173–9.PubMedCrossRef
33.
Wurdinger S, Herzog AB, Fischer DR, et al. Differentiation of phyllodes breast tumors from fibroadenomas on MRI. AJR Am J Roentgenol. 2005;185(5):1317–21.PubMedCrossRef
34.
Yoo JL, Woo OH, Kim YK, et al. Can MR imaging contribute in characterizing well-circumscribed breast carcinomas? Radiographics. 2010;30(6):1689–702.PubMedCrossRef
35.
Yabuuchi H, Soeda H, Matsuo Y, et al. Phyllodes tumor of the breast: correlation between MR findings and histologic grade. Radiology. 2006;241(3):702–9.PubMedCrossRef
36.
Jacklin RK, Ridgway PF, Ziprin P, Healy V, Hadjiminas D, Darzi A. Optimising preoperative diagnosis in phyllodes tumour of the breast. J Clin Pathol. 2006;59(5):454–9.PubMedPubMedCentralCrossRef
37.
Yasir S, Gamez R, Jenkins S, Visscher DW, Nassar A. Significant histologic features differentiating cellular fibroadenoma from phyllodes tumor on core needle biopsy specimens. Am J Clin Pathol. 2014;142(3):362–9.PubMedCrossRef
38.
Lawton TJ, Acs G, Argani P, et al. Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors. Int J Surg Pathol. 2014;22(8):695–8.PubMedPubMedCentralCrossRef
39.
Giri D. Recurrent challenges in the evaluation of fibroepithelial lesions. Arch Pathol Lab Med. 2009;133(5):713–21.PubMedCrossRef
40.
Zhou ZR, Wang CC, Yang ZZ, Yu XL, Guo XM. Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence. J Thorac Dis. 2016;8(11):3361–8.PubMedPubMedCentralCrossRef
41.
•• Rosenberger LH, Thomas SM, Nimbkar SN, et al. Contemporary multi-institutional cohort of 550 cases of phyllodes tumors (2007–2017) demonstrates a need for more individualized margin guidelines. J Clin Oncol. 2021;39(3):178–89. This establishes local recurrence rates in modern cohort and encourages individualized guidelines.PubMedCrossRef
42.
43.
Co M, Chen C, Tsang JY, Tse G, Kwong A. Mammary phyllodes tumour: a 15-year multicentre clinical review. J Clin Pathol. 2018;71(6):493–7.PubMedCrossRef
44.
Ogunbiyi S, Perry A, Jakate K, Simpson J, George R. Phyllodes tumour of the breast and margins: how much is enough. Can J Surg. 2019;62(1):E19–21.PubMedPubMedCentralCrossRef
45.
• Lu Y, Chen Y, Zhu L, et al. Local recurrence of benign, borderline, and malignant phyllodes tumors of the breast: a systematic review and meta-analysis. Ann Surg Oncol. 2019;26(5):1263–75. Meta-analysis evaluating factors associated with local recurrence in phyllodes tumors with lengthy follow-up.PubMedCrossRef
46.
Moutte A, Chopin N, Faure C, et al. Surgical management of benign and borderline phyllodes tumors of the breast. Breast J. 2016;22(5):547–52.PubMedCrossRef
47.
Cowan ML, Argani P, Cimino-Mathews A. Benign and low-grade fibroepithelial neoplasms of the breast have low recurrence rate after positive surgical margins. Mod Pathol. 2016;29(3):259–65.PubMedCrossRef
48.
Moo TA, Alabdulkareem H, Tam A, et al. Association between recurrence and re-excision for close and positive margins versus observation in patients with benign phyllodes tumors. Ann Surg Oncol. 2017;24(10):3088–92.PubMedCrossRef
49.
Qian Y, Quan ML, Ogilvi T, Bouchard-Fortier A. Surgical management of benign phyllodes tumours of the breast: is wide local excision really necessary? Can J Surg. 2018;61(6):17617.PubMedCrossRef
50.
• Diego EJ, Rosenberger LH, Deng X, McGuire KP. Margin management and adjuvant therapy for phyllodes tumors: practice patterns of the American Society of Breast Surgeons members. Ann Surg Oncol. 2022;29(10):6151–61. Details current practice in phyllodes management.PubMedCrossRef
51.
52.
53.
• Sars C, Sackey H, Frisell J, et al. Current clinical practice in the management of phyllodes tumors of the breast: an international cross-sectional study among surgeons and oncologists. Breast Cancer Res Treat. 2023;199(2):293–304. Meta-analysis evaluating factors associated with local recurrence in phyllodes tumors with lengthy follow-up.PubMedPubMedCentralCrossRef
54.
Onkendi EO, Jimenez RE, Spears GM, Harmsen WS, Ballman KV, Hieken TJ. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome. Ann Surg Oncol. 2014;21(10):3304–9.PubMedCrossRef
55.
Yom CK, Han W, Kim SW, Park SY, Park IA, Noh DY. Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast. Ann Surg Oncol. 2015;22(9):2912–8.PubMedCrossRef
56.
Choi N, Kim K, Shin KH, et al. Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG 16–08). Breast Cancer Res Treat. 2018;171(2):335–44.PubMedCrossRef
57.
Yoon KH, Kang E, Kim EK, Park SY, Shin HC. Recurrence is not associated with margin status in phyllodes tumor. Ann Surg Oncol. 2023;30(4):2154–61.PubMedCrossRef
58.
Tremblay-LeMay R, Hogue JC, Provencher L, et al. How wide should margins be for phyllodes tumors of the breast? Breast J. 2017;23(3):315–22.PubMedCrossRef
59.
Zeng S, Zhang X, Yang D, Wang X, Ren G. Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: a systematic review and meta-analysis. Mol Clin Oncol. 2015;3(3):663–71.PubMedPubMedCentralCrossRef
60.
• Chao X, Chen K, Zeng J, et al. Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):372. Meta-analysis of adjuvant therapy in phyllodes management.PubMedPubMedCentralCrossRef
61.
Jang JH, Choi MY, Lee SK, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol. 2012;19(8):2612–7.PubMedCrossRef
62.
63.
Neron M, Sajous C, Thezenas S, et al. Surgical margins and adjuvant therapies in malignant phyllodes tumors of the breast: a multicenter retrospective study. Ann Surg Oncol. 2020;27(6):1818–27.PubMedCrossRef
64.
Gutnik L, Ren Y, Thomas SM, et al. Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast. J Surg Oncol. 2022;125(6):947–57.PubMedPubMedCentralCrossRef
65.
Gnerlich JL, Williams RT, Yao K, Jaskowiak N, Kulkarni SA. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998–2009. Ann Surg Oncol. 2014;21(4):1222–30.PubMedCrossRef
66.
Koh VCY, Thike AA, Tan PH. Distant metastases in phyllodes tumours of the breast: an overview. Appl Cancer Res. 2017;37(1):15.CrossRef
67.
Parkes A, Wang WL, Patel S, et al. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021;186(3):871–82.PubMedCrossRef
68.
Li GZ, Raut CP, Hunt KK, Feng M, Chugh R. Breast sarcomas, phyllodes tumors, and desmoid tumors: epidemiology, diagnosis, staging, and histology-specific management considerations. Am Soc Clin Oncol Educ Book. 2021;41:390–404.PubMedCrossRef
69.
Adesoye T, Neuman HB, Wilke LG, Schumacher JR, Steiman J, Greenberg CC. Current trends in the management of phyllodes tumors of the breast. Ann Surg Oncol. 2016;23(10):3199–205.PubMedPubMedCentralCrossRef
Metadaten
Titel
Contemporary Management of Phyllodes Tumors
verfasst von
Tina Bharani
Laura S. Dominici
Publikationsdatum
27.02.2024
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 2/2024
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-024-00536-3

Weitere Artikel der Ausgabe 2/2024

Long-Term Burden of Breast Cancer-Related Lymphedema

  • Review

Locoregional Therapies for Treatment of Invasive Breast Cancer: Review of Contemporary Clinical Trials

  • Review

Current Status of Imaging for Breast Cancer Staging

  • Review

Minimally Invasive Breast Cancer: How to Find Early Breast Cancers

Surgery for Lymphedema Prevention and Treatment

  • Review

Surgical Management of Lymphedema: Prophylactic and Therapeutic Operations

  • Review

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise